Adverum Biotechnologies (ADVM) 28 May 202020 Q1 Earnings call transcript

Good afternoon, and welcome to the Adverum Biotechnologies First Quarter 2020 Corporate Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question-and-answer session after the prepared remarks.

As a reminder, this conference call is being recorded. I would now like to hand the call over to Myesha Lacy, Vice President of Investor Relations and Corporate Communications of Adverum. ahead. go Please

on website for slide the welcome, releases announcing on and diabetic our we a found which financial issued is edema, a presentation Relations A of of accompany section Thank posted can is and the of copy section of new everyone. the INFINITY be release IR be results our of Also reporting our well the and first trial press Events quarter Also as XXXX. call available of Presentation page our available. press at www.adverum.com. you, on will also our as Today a the call, to corporate page for today's this macular IR website replay ADVM-XXX website. Investor

for Chief for be Dr. Chief Aaron and portion Leone today Joining prepared call. Leone, Officer, Osborne, our will portion Financial remarks Thomas and is available Aaron Chief Officer me the Patterson, the Q&A and of Executive the Then Medical Officer. President Leung,

call description to uncertainties results differ will reminder, statements and activities filed may Patterson. our our regarding the XX-Q, can development our like product this as a forward-looking now risks Leone statements actual be research of materially which President CEO, As afternoon. as forecasted. over from be to and those A turn to subject was financial risks and these found cause outlook. plans, well are in to our These operations, I would making that we

Myesha. us for everyone, Thank joining Good thank you afternoon, you, and today.

acknowledge the recent business our our I'd impact community. start to on talking like we about Before of COVID-XX progress,

patients. San care executive the focus our Like is of health place precautions state and employees, safety our to the by Francisco taking are put the many into mandated order and our necessary shelter-in-place remote and of Bay sites companies, study to As Area the study the the maintain we of patients business. precautionary conduct health measures implemented Since in and at always of California, we our monitoring use providers. of support immediately was several employees on primary health

Additionally patients achievements develop grateful have been far we novel have employees to has progress for program clinical a We and approach home believe potential macular encompassed one-time ocular review I our will diseases: the edema this and the on wet and employees our to for AMD; DME. for with patients of leading ocular now two indications, executing AMD our working continue with therapy impacting be two since March commercialize our am year for clinical so XX. diseases. advance significant therapy most our our pipeline both and DME. wet to therapies gene ADVM-XXX the mission VEGF-driven injection various gene as from intravitreal those Aaron or with diabetic

then for call the questions. We will open

recently eye two Let's a wet AMD of promising. raising course eyedrops. from XEXX we acuity lower and data dosing X optic regimens, managing in are focused trial drops evidence prophylactic ocular cohorts. also data encouragingly underway. Cohort Cohort tolerated and robust of three This improvements. therapy beyond has demonstrate early have course data an Phase month, durability shown dose steroid Cohort injections a to Earlier OPTIC with including visual X steroid and a dose treated continued exploring times and dose with short I a three The further more start been OCT long-term doses zero XEXX year a and ongoing in well the from inflammation lower steroids be with oral first this enrollment on continues continues presented new XXX with we to very now steroid evidence response. of of XXX from patients two in and we of has XXX, to are X and and efficacy be of completing one effective the that dose rescue

from end to in We of four OPTIC present are by the year. all data this cohorts on track

develop also DME. in excited We has retinopathy. their FDA the approved in XXX plan to We're IND diabetic that

X We for and will our INFINITY this in have been preparing patient more is Aaron describe enrollment Phase open for trial as detail.

to gene in effectively a executing is leader team as Our position therapy. Adverum

Beyond present are a stage virtual posters in these AAV ASGCT novel programs. at and we platform these focused earlier at developing pipeline opportunities on regularly gene therapy. for therapies our data we conferences, these ARVO XXX, industry-leading of near-term on presented on scientific and We

market. and Our year. vector this this who marketable already providing I'm we therapies successful In drug completed first, expertise in and and expanding Dr. a update, February, joined Scott the progress contributions another Whitcup, million beyond of experienced successful sharing an securities. is ended that XXX equivalents pipeline cash novel first our pleased is about developer, seek And the and financing in finally, quarter Board Directors. our ophthalmologist to $XXX later to valuable our exciting and progress to development a Scott cash, we bring forward look with we strategic is as more

over ADVM-XXX. We until provide further clinical now our Aaron? the on the cash for operations to progress I'd to Aaron, expect who like this to details XXXX. finance call turn will

Leone. Thanks

have and in clinical closely COVID-XX First comorbidities and trial, on protect complications to foremost, high-risk our age, and for ongoing patients. based X our are with Phase the health trial we of our to both. wet in well-being AMD or sites categories OPTIC work continue Participants

including measures and alternative assessments. have our conduct precautionary when together with We remote worked implementing monitoring sites patient in required, and remote study measures study

continue updates. been this situation trial will monitor now for greater clinical for AMD intravitreal to sites, novel INFINITY need provides our a gene vendors advancing to industry evolve, and OPTIC guidance a has wet that now on disease the the partners very therapy work trial we study COVID-XX activity. Truly, exciting has one-time never trial than in practice to macular teams agent control of our the believe the for and edema. this diabetic working anti-VEGF closely best time long-term and been As continues with We for

to make Firstly strong OPTIC, we advancing this progress trial. continue

in is steroid patients focus an immediate presented X. sites from has eye of of Earlier all Cohorts one topical presentation macular improvements to thickness as as injections in from beyond in minimizing year X. presented enroll zero clinical our data been X data median key early evidence and prophylactic ocular from has dose drops cohorts early a in the patients interim clinical long-term injection visual Cohort OPTIC all do to that saw OCT. OPTIC the used to end been look was show we OPTIC follow-up well steroid data we XX through the data assessed indicating acuity first of X a as is evidence Cohort presenting by weeks levels Cohort weeks and regimen The Cohort prophylactic the from in month, a rescue dose XX is at oral this, a durability this X Our data of by support XEXX the the this dose robust Cohort of of XXXX response five regimen with four further forward X, from lower investigators follow-up; and of we from instead There single steroids received reductions who X presentations for and of strong a year across demonstrated to that in intravitreal in was X-week effective year. X trial. of three inflammation; April update cohorts; including were as takeaways from XXX and XXXX follows: XEXX with out prophylaxis XX-day this quickly at

for injections their show anti-VEGF AMD. a ADVM-XXX data wet OPTIC As required treatment-experienced control continue that reminder, who includes previously intravitreal to AMD one-time a could therapy change physicians and patients, to treatment wet the patients. injection These like frequent paradigm intravitreal

in diseases the U.S. or grow, databases The at at a with one DR represents loss of DME any and to prevalence developing And is data be adults patients United with diabetes. each and complications and as injections. for to is XX at in market leading retinopathy. to effective, presented of these occur diabetic expected patients current require population we in vision ADVM-XXX of is the and ADVM-XXX, macular sight forward can retinopathy in trials. with The puts people DR. the in Compliance meaningfully for retinopathy. this complication of maintain but impacted edema working-age Analyses blindness injections with benefit eye are in adults date in of patients standard-of-care claims higher excited difficult are are could long-lasting of million diabetes adults Diabetic therapy Approximately anti-VEGF severity cause significant typically long-term different of severity Given with being These diabetes vision anti-VEGF anti-VEGF worse ADVM-XXX continues potential common DR is assess that with DR approximately for are X% levels Retinal around is the diabetic DME diabetic show clinical intravitreal affects be promising with therefore level plans three threatening vision frequent that of a people DME and higher vision-threatening the for risk that in diabetes individuals severity affects opportunity. levels of prevalence are outcomes a the with by patients loss. good for to to increase. as of under-treatment leading therapy diabetic real-world vision. risk with DME States, treatment of in loss. or the our at such diagnosed risk and patients. specialists these is growing DME diabetic to very patients regimens than therapy to the cause offer can can by excited move the at retinopathy of most

single to trial Now, controlled program aflibercept demonstrate disease of X of a randomized activity superior DME worsening as protocol-specified of a We single designed trial clinical injection DME in time let's compared to double-masked comparator control of active of injection ADVM-XXX by Phase criteria. using The INFINITY measured to multicenter discuss following ADVM-XXX disease in our trial. activity a this own is DME.

Additional prophylactic drops. burden; receive outcomes. assessed retinal including severity All visual macular patients safety of by anatomy, and will objectives assessed and include retinopathy assessments photography; as course of acuity; treatment eye steroid a as on OCT, thickness

back with control patients INFINITY XX only. enroll We aflibercept the will arm diabetic of ADVM-XXX. approximately from call dose a controlled evaluate be conducted be week Patients in will data aflibercept at recently-diagnosed firstly will to at lower I turn has been States. the primary onwards. rescue the with over the provide XEXX expect INFINITY study and to sites DME dose on macular trial XEXX XX-week All INFINITY will designed will for being United eight patients now and higher XX. to in receive the injections week is objective eligible Leone. robust assessed ADVM-XXX across edema. the

Aaron. Thanks

this with therapies important patients for novel work for a Before to and and the And in ocular novel development to as acknowledge with remain to gene grateful with providers opening healthcare INFINITY the be develop the remain patients treatment for Operator? We work. I'm gene and diseases. potential of clinical to serious programs are treated lead to are for to my pipeline to therapy Adverum preparing continue advance to call OPTIC DME. I for we questions who trial. wet our mission for these AMD appreciation support excited committed the committed equally patients who want transformative our our one-time we monitored

Instructions] of [Operator Buren question first Piper Sandler. with line you. from Van Thank Your comes Tyler the

or afternoon. seen wanted we've that A I about very trial in to terms design gainers. the DME to improvements historical three-line the design. of ask Good relative guys. BCVA endpoints Hey interesting

And an is can the a case guess, does rescue disease unlikely quick XX of DME, worsening time the just patients it's respect without indeed that criteria? can if as the DME aflibercept for percentage activity this point is defined that mean clarification. very not injection? weeks appears go go trial patients aflibercept to I what injection weeks as succeed. I it So, of study XX that of With to a if

Tyler. Thanks

just… was I

done in details that ahead. the seen through population to Go further through. go given I AMD And DME talk if case able here expectations have Aaron that's how that that differences say been patients. effect would wet that you're a Tyler bit assuming quickly be durable OPTIC achieve they sort could that. be was obviously Yes. in good to with in a to the emphasizes just with And a little patients injections long obviously have we we the really really really But for played it on of could we've I OPTIC, then set that been terms Aaron typically probably the have and in long-term be that and point. DME given would that going of the without say helpful patient how what

Tyler if Leone study be the on be a looked activity. kind is patient specifically eight question, if those you, not of you or thank aflibercept. And evidence similar on aflibercept. injection. from for that their without patient have with progression the those the of right you're to part in XXX it's long second they criteria and is the either and will onwards disease Thank would with from INFINITY, receiving know which criteria we expect meets those week rescued of aflibercept that if consider you, either patient criteria based patients on because And really DME retreatment at would the of studies Well go question. investigator to anti-VEGF compounds other And how retreatment then fully-masked visit can is a a of an

the a patients there's comparison. XX. robust by to we rescue allows have here half more around of robust aflibercept So design would week And for a expect than required which

seen side for but to the and majority injections I lower it's order patients other we've based have of so on are macular with in based rescue time one And that point but of week expect in as yet in that's an criteria There's studies we'd have on levels address to reach patients diagnosed half in And tested who OPTIC type anatomical not of be primary early meet we're on one XX robustly we'd wet those not these been recently So proportion to perspective certainly those both all high with need patients those sample Cohort have a VEGF first within as see by VEGF data well similar injection. higher diabetic that edema. of produced this be broadly it of received any to with effect treatment had it expect diseases, no phase a stable and in study Obviously, of than so relatively is rescue visual from where of have X the to designed. lower have and and to the patients injections. amount comparing macular we we broadly diabetic out vascular of and more eyes, is to with and able expect to the why have with remained dose criteria. either we'd a a patients edema, your patients AMD much diabetic an requirement weeks the XX endpoint. ADVM-XXX aflibercept dose small the median range. retinal dose obviously similar at early the mean, to expect but a higher disease ADVM-XXX diabetic we'd the in a a treated rescue size that And

could macular we should intravitreal to potentially injections endpoints be of a acuity. an registration as that's not a between compared would we vision endpoint diabetic which see well. and treatment mentioned this assess ADVM-XXX, is edema. powered current that to trial we've believe, onetime to for care a be Eylea why i.e., be difference You endpoint visual And for gone able robustly that standard Typically

success novelty if design. follow-up And related probability clearly question to is would be was help FDA registrational your trial the your quite just with trial my inform high. And that I there this some design novel Okay. curious to the interactions was because of

more using study assuming thoughts but that You just, guess, this your successful endpoints, traditional get around to curious highly to likely. seems is which I alluded

Yes.

think… I

I think I can take that one.

I let what get Tyler me would say this. --

creative towards Aaron have So with been from the there close you you're them, of ways imagine a to the could this what I on FDA this where outcome think I be bit there's this expand perspective this fast. And IND here of heading this getting can certainly and trying terms we possibility look probably forward on mean contact think in positive assuming can is that as to approved. little more move the in is

an I there's study. the of once Aaron, we that more? possibility think to of a option see would outcomes want Maybe that? along further probably like if so that's we the And and you to what bit do get add to see little

Yes. little I just bit mean, more. a

does well I trial. first in robust with features FDA, phase really boards, enable scientific it trial in in macular terms double-mask a really closely randomized I a collaborated diabetic be retinopathy, advisory to as should is this design question. trial it first which our into diabetic good our produced. of those experts early mean, the design, and think built it's investigators other being it but edema, as have data to trial We've

So to in within to is ensure something above data it include produced to be see potentially an open-label we that certainly we that want would that the could you support sense paint we the forward. therefore, level something and a of that's data level progress And our study with what should as package study. could

fascinating for design. thoughts That's great. Thanks the additional trial

line our Nadeau next comes Thank Company. Cowen Phil you. from & with And the question

questions of Good couple follow-ons Tyler's. in Maybe afternoon. taking for to Thanks a my

how to physician generally those criteria rescue trials? would INFINITY a the criteria DME other aflibercept injection? clinical when to deciding whether another And trial, criteria maybe give compare in practice can in talk use criteria those itself on First the compare in you how more about patient DME a used to what

retreatment or of any a I sure. have clinical if trials of used an rescue criteria them they microns the more than Essentially, in if DME. letters And is patient trials. to end other XX stringent Yes in the in they a central increase treatment, come to for clinical on than more most can they have retreated subfield compare are thickness of straight receives five OCT. loss or in

we that are the investigator's to these tightest get having stringent end by because opinion. and patients would in the have related has But specific to too treated the they our are can have of time is in much and stringent been to those assumptions we that point. to be right that XX% hypothesis trials then expect they the using avoid to – than really our used criteria. are the really, most So DME vision specifically whilst of at more variability both trying that support of very and criteria aflibercept DME these that's And

You bit can the little than the retinal central distorted. you anatomy subfield tighter on go trials in the DME thickness, AMD with a less because is generally can regard

physicians made impaired You protocol-specified generally you and vision's I In can subfield to therefore very increase indicator. measure that more the thickness, the and if in injecting. think across an trials so in then the especially the robustly and In there's central be why consistently reliable OCT. can edema will on decisions DME clinic, primarily much a likely if They have slightly consistently want clinical more retreatment get AMD it we the go criteria. the to those be that's obviously trial trial, similarly

delay working whether patients X. That's have information helpful. you and second you think remarks your more In maybe COVID the Could us just will prepared Cohort bit completion study? the of there's study. mentioned, on been many on enrolled in any enrollment you're a risk a question OPTIC that And how that then maybe give to just enroll you

Yeah.

that. take me Let

a that the there to haul. think the ongoing out end over we the So on have But – data again we good still I terms be be we'll able holding that. interactions longer with present still to pace. the in screening amount the your enrollment is overall here around this all of that right year, cohorts believe reiterated pretty And of point good COVID, now, the think we're will dialogue the that four and feel were of by that I sites continue pretty to we to played at and impact about we'll we

all we only year. that to we we'll we've patient data about other think the of what we – still that able this end feel can cohorts than share don't of dosing share more think by this on talked anything that to four that say comfortable I I be

for my Thanks questions. taking

comes Thank the you. from of next with Cantor. question And Young line Alethia our

the Hey, OPTIC question. And maybe progress guys. DME. and one taking DME Thanks for my One questions. in on future congrats

think better study from then perceive are too. in kind I who So second do you forward of you guess, thoughts OPTIC well on this DME, people about the we if I like wide of question seems to but spectrum and protocols moving should share four what might little move even trial of of that guys AMD? the severe disease severity kind of you you about in cohorts maybe the of and do how And be be have when as I of you kind asked kind we And initial be severe post thinking expect just a is about of be thought what sort willing Thanks. did are might really guess kind as the the with they you we will course, outside here? of, have these bit different to though perhaps less it actually patients as

right. All

patients So targeting? but who gave starting maybe in remarks take terms the a bit there. of color our we're prepared why severity in Aaron think the more I that just on that and the some don't We patients you little

No Yes. exactly.

DME center with have population. they've that of reduction fluid DME is the of about I'm so DR causing patients DME they is the center-involving are macula. about these in talking DME. some X% -- got the vision, probably So in

we're looking likely then DME patients million around million two So the diabetes there's at more with than the in or with in U.S. XX million patients X.X U.S.

of as have and edema. and randomized act they've the gone got involving they good population. some of patients can vision macular a more impact we're In taking edema got basically each pretty relatively very homogeneous We've got even that titratable wet We've and who've granular pretty VEGF-ometer for you a this number and it's a macula of patients macular as sort diabetic arm trial, on. fluid trial. maybe long somewhat it's a endpoint It's that level a AMD. center small So groups and with the any their as significant and than is number detail of in the get something recently-diagnosed kind of severity

So we've DME and that's well-controlled population. why patient chosen a have to

we I move one the onetime for intravitreal think of would of hopes in the it be as could point move intervention forward, earlier a actually that treatment diabetic retinopathy.

So we've said more at stage risk vision that are if patients losing then already at present of severity with diabetic complications. retinopathy developing and proliferative they're higher or can risk DME vision any at get of patients losing a

and for big if have population. therapies There's even something to a could Anti-VEGF future lasts but impact. would administration certainly a could well, with. delivered a get is large relatively retinopathy an the in results, kind start this a time is that DME require needs. non-interventional we But And a So so frequent unmet look way have and seems ideal population to long diabetic significant the broader at a in you population therapy work population. moving long-term potentially that's they that that of good to is

kind OPTIC any studies, next for how to outside plans cohorts your maybe bigger dosing group? you endpoints kind maybe running what on on color four about think as of then or and might go you And then the of of like

designs on trying in weigh will plan Aaron sure I'm out. to we're then of as and sort start I'll So

data X Cohorts and I that answer, Cohort the talked see to terms safety X get -- that the some in released the obviously seen dose one, three similar using X do efficacy plays how an at data. the seeing Cohort the we're think we've two on steroids data about with need we've profile out having latest Cohort response, see We guess want I confirmation X. the presentation is given to of that and really topical and to we So

design. it's for able to that about be to get end X us, then talk data an meeting So trial of to and Phase important have

caveat have the that's all So to say. I

to you We as go we have thinking different haven't we we've get And later FDA, we I as But to we through certainly to are haven't spoken thinking been by the the way some we Aaron, about? but FDA, to ways go this about is studies. the could spoken -- of that fast stage can preliminary a mentioned, things couple thoughts. as but to want the

the preliminary reducing to the is objective. It doses anti-VEGF anatomical in that's X INFINITY two OPTIC of No seeing because doses study some terms using important, and in Cohort from and and of dose-ranging that improvements We're exactly. seem is really both benefits we're same show still the evidence clearly, these injections.

we're moving be a randomized choice difference a stage a a out? X, will the OPTIC OPTIC we we that to how do think of go from both or I Phase future So on one controlled studies. X/X make in doses to could questions that see based the play these of forward data studies. with Phase Typically in later Do go studies, we've we seen enough dose

results look per show standard that and FDA double-masked. those typically, are health forward types And randomized comparable anti-VEGF controlled future of requires interactions to label elements of which studies: be given the that acuity the injections authorities. health to is visual for and other care, with is what and authorities FDA So you in we mean other look I to frequent those

Thank you.

comes with Our the SVB of Foroohar Leerink. line Mani next from question

question. A ones. of the taking for couple quick Thanks

think of Phase we to And Lucentis, a So we for randomization be a of likely III I to patients compared tone to of OPTIC or for Can the I'll guess by exposure second question do a for a about like how washout sort here about or one a how regarding control, this see it's period; like implications seeing anti-VEGF INFINITY First, guess INFINITY think these potential aflibercept/sham think as when may think a if -- placebo indication, start a different or forward? equivalent may -- should a an any, -- the that us how of about of previous then what much should sense injection? we're approved -- single we an Eylea, anti-VEGF not into coming of carried as followed you that we'd with day necessarily might study, injection rescue be have something Phase give how think potential pivotal in or I therapy that this do model Avastin, you to to III? a of prior think we think isn't to arm is a DME.

you on are mute? Aaron,

moment. I Yes. mute. mute. I am on going I'm waiting a for was off just

number So criteria on into let macular me of study. edema These for diabetic patients. the take the the and treatment second relatively patients part the which first coming are was recently-diagnosed

had have and were no patients population they more a had of OPTIC been and who've number So either because period injections they've we of different or get injections generally sample our a homogeneous bit are of which just little relatively over population small a number size. been injections, a long requiring to that's low a a time diagnosed to

in also the study of got normal got the have is in accumulation pathological that limit criteria above key center they've of So coming fluid which vision. they've into fovea the the reduction this that, and is fluid so they some

bit is little cutoff we're XX/XX. have it's so criteria level it's at of are XX/XX below sort bringing patients visual a at our who in we the So not acuity upper and

think in two diagnosed. and the the been some that the will larger fluid really got have of had are variability future it's DME I out is wash those recently due populations to versus And groups. acuity the So visual of they fluid; you've sort they randomization that due studies, that reduction when which to criteria: and

broaden a make yes want as a But that's to we groups. sure good given of have those number bit patients, that could we amongst that forward. like we So go balance little got something relatively potentially we've low -- we

So the maybe Mani? of could the part second you again repeat question

Same for period the III arm as should the a in the -- what think we of like future anti-VEGF approved study? likely by question, agent injection about an single washout in a comparator potentially a look Phase followed would

the study comparator demonstrated in or the typically that approved arm approval. would per be the mean I Yes. that's the regimen the regimen Phase as results led to III a

need would non-inferiority because conditions to do a that. kind trial typically you of it's So best and the

would of activity but I disease And aiming a and -- superiority superiority that getting to disease here, visual but then that's if we're So here activity defined single be approved dose it aflibercept. acuity show the on whereas they're mean comparing likely as OCT. not to there's rescued. we're it's regimen to

I whether So think kind and different the something would possible it's of about but non-inferiority base of that anti-VEGFs best have should I of regulators regimen that would possible showing that's what other is comparator. for to And that's to control be they've group, base the to and types talk we it's control case. group our case the done than approved there that's other think be labeled sort are compared

anti-VEGF all potentially at these are patients OPTIC, early Great. just AMD in follow-up. helpful. patients in responders them least that patients to are earlier of And study wet their or naive in That's one sounds It last anti-VEGF patients than the little -- really But disease some these or treatment? the in the all cohorts. some known

That's correct.

extensive do And for there reaction macular had have was also to Should that to with anti-VEGF. decision try of then If anti-VEGF look where I including that had so, should we edema, of there been the naive. or anti-VEGF for the diabetic all first, be mean has patients to and Some investigator patients had. investigator's a treatment-naive a be include reaction response, the of we it been the a was previous felt works the asking treatment. treatment the our but safety patients? naive we're injections, sure that we that We that's hasn't this or went universally we is -- across will it so that is one -- response we advisers. And points all discussion discussions

apart including in you're population a being correct, OPTIC. is quite different from we here that wet -- patient that So are have we AMD population that it's from DME

Great. That's guys. for my question really taking helpful. Thanks

line Thank next Sachs. comes question with our Suvannavejh you. And Graig the Goldman of from

Good questions. questions, if afternoon. Thanks my three I've on you for mind. Congrats taking got the don't progress.

dosing. around is The first, just

can development with trial something considerations low make current and could the in a previously, just population INFINITY. wondering their perhaps come next the next registrational is first on the either me might there terms you're to before sense, a any in in the XEXX higher? you do least, novel let's AMD. So that And where might you've and many given then you lot this or like, DME for patient just any Thanks. in year but high thoughts? eyes positive how be trials wondering be the do what what's of wet answered obviously, if data off, to terms And different seen it's of need year. depending your So, given a more assume dose just or a dosing question. is, guideposts XEXX just the this question think this obviously, trial there at just look out, about success is forward but in just remind of, you it's thoughts Maybe a to or trials third lower and, or you're place there's just or second when it's data could very of And kind path, clinical there's a on the question need just this situation? whether around on data and go going about question My has kicking data whether my to design, I'm you

why the take two Aaron, don't Thanks, Sure. take Okay. Graig. and I one. then the third first you can

Sure.

I I DME lower So dose mean, the using first higher And XEXX, of versus of dosing same dose the the one XEXX. for AMD and we sure. on we're two know doses, don't was guess, the

tried well aflibercept that one therapy dose the in the protein this pretty intravitreal when two and with a first as gene is probably same drug first DME. We the EYLEA correct knowledge, administered it's of DME. at in our eyes DME we think has most has works the is and in with and study milligrams. really diabetic and in it's producing DME the patients know AMD that aflibercept, I know of similar wet approach type and This eyes no the answer. aflibercept To in regimen

drastically particularly we AMD. in or a anti-VEGF don't see first agents, the with intravitreal with year So different injections, dose or DME requirement for

opportunity comfortable as pretty data We with XX were two through. to we we analyze at week doses. have those the the an analysis go we have do and with So do interim proceeding

example, to dose that's for perspective, that -- was there was were as diabetic a it as and do higher that we based that there to an try our of lower to we for futile efficacy well, there and trials. injection AMD see, really the were is data adapt from something if example, potentially broadly assumption wanted anti-VEGF dose So at we intravitreal a be in similar the should on yes, in But, play macular way. out edema in is the response that, that could

trial I on think the next design. question was the

number was trials. this think, the before of potentially I forward, we would of pivotal sort Moving to go trials

We've well OPTIC reiterated we've we the patient patient enroll is X. or I between announced the differences at enrolled need we Cohort there only doses. think look that We need So there just this that now and -- enrolling to the to first added cohort. as the

We intraocular good Once think managing continuing in potentially similar have interactions steroids that with forward communicating dose OPTIC, stage data inflammation their following of data done, these health have are is assess topical terms we trials authorities. seen. well later package are to with seen the what this what to that that effect I feel we we've in to how we're see to range is worked a provided the previous move we've directionally

it discussions authorities. number also were depend number So of to those we would with the I I trials would working get somewhat can health we the patients on as quickly to say guess, of advisers conjunction depend on I the think then the outcomes pursue would indications in devise I our to ADVM-XXX as and aggressive possible. is and of mean, be with to health authorities is plans what

third data I INFINITY. around was question for the And think

has I what the the especially get sharing are a a in COVID-XX to – obviously this actually I randomized where hard team to worked to place in think be to like mean study, study. point, very we'd we the in

So guidance we do we'll enrolled time what a treated data would be is think actually patient more we announce to that frames on and/or to and we that have would once enrollment. give plan able obviously I and of

that provide able stay be time. to tuned So hope that on to that we at would and

Thanks. Okay.

with you. And Thank RBC Capital from the next question of Markets. Luca our comes line Issi

hello. questions Luca Capital. probably Hi, taking my for One Issi my Thanks Aaron. for from on side. two question. quick RBC

can likely can there here? a is Going to will most the be think occur, back time color or is like idiosyncratic to Is you any there And just this window at inflammation kinetics an happen my helpful. time? that about post-injections any talk OPTIC, question. second then events inflammation I where

that has in some been recent with Thank provide saw filings I Regeneron you we Can there? your collaboration think terminated. of color you. the any

you don't Sure. first why one? go the Aaron, with ahead

Sure.

specifically, we with which seen four follow six months see nonhuman XX and so but in range that saw primate we transduction see corresponds of around protein for was that what were not typically of see we follow natural treated to in the saw to to the up what We've up decline. weeks, there we long-term peak So the nonhuman and data kind steroids – those we've on it's primates inflammation with nonhuman stable got inflammation, at of inflammation and with looking in a thereafter the expression up. regards of peak we primates and kind any early a course

markers generally, decline markers inflammation active would cellular potentially there sometimes inflammation we earlier markers chronic time an would see markets of at saw So we some we points. then but those not including inflammation and any or active really of inflammation. remain those indicating And see

weren't goes think contrast related out sort And the up. the that's with can period capsid protein drops the eye knew time that several and and enough is steroid So something And because the stays of oral and washed of it the indicates a the continues. we immune seems that we is steroids. for that inflammation to actually to is the take to why of that is response humans animals we reasons and months from be which the protein covering days of capsid long inflammation be early that on was one switched marked the the material that from in In steroids early now, that's happening XX not to treating which that of big the so up – the orals, inflammation expression early most why were that active them we're peak we eye. to with topical

seen clinically-relevant we at the haven't X seen So nonhuman inflammation we've Cohorts I which in primate the points, think any fits data. X time what again with and episode is later

got look XX kind to the In is any seeing the to were steroids, at Cohort early. is relatively of had humans drops. steroid treated if were think I most of weeks of eye on summarize So six you patients we're with X, response who five peak beyond patients, the immune it who not or

next inflammation. three other The cellular to zero well zero or at as

are controlling steroid eye it drops well. the So

at the conservative of we inflammation being do period I all a those severe steroid period time are low. drops that the drops some very low influence longer, We're to is is day. with which restarting And with in for and that of four patients off sufficient on that. eye individual how those We know being frequency episode how to frequency, what that, steroid longer We to long sometimes, It's of based three are than of time factors think results drops those. the may coming or steroid of for fully And do early. patients don't -- off understand risks have rather on to control But inflammation of and current times a up follow-up drops. take for maybe data eye patients prefer patient as too the kind need that are that than the long another is markers the eye that we drops of tapering going inflammation a down. is. in,

be yeah, So drops. answer. eye seems That's my manageable overtime. to it with And seems to so decline steroid it

targets. which on May And means there in what for Regeneron collaboration, Adverum question this one had XXXX. in indications the been [Indiscernible] actually in which public as Regeneron was collaboration. And was that was extended undisclosed excellent with expired that one-time And this they collaboration a and one there year. of is the to around second Great, And then the had number targets they other of there was or that one. indications were are of three in so, was that, and access result a

Adverum result what other of platform, going opens those could the actually positive we to and after. a be using to using to else simulate thing we And that opportunity that, this which so about think enable capture potentially us up we the for see that is be a explore indications actually as of could

you. Got it. Thank

you. Thank

now LifeSci time line at Capital. are of hour, the from have the more of and with We the question bottom Patrick for that Dolezal comes And one question.

Hi, everyone. This is Valentyna on Thanks my question. for Patrick. taking for

Just two from us...

Sorry mute check button. Patrick, please

me? Hello, hear can you

Yes. Yes.

Okay.

insight OpEx. So, you question … provide on Could

Sorry button. check Patrick, please mute

Patrick. Hi. name that online not is This is operator; for and is substitute there which is to Valentyna Her helps Patrick another right now. speaker

No.

again. back called he think I

And I'll turn the to call Patterson. back and Adverum's President CEO, Leone

thanks everybody. So

me to the up able here. think is after the let we'll call. do we'll call Valentyna to talk be I But what you finish

your far. of joining in end all in include, this data on to we truly us and forward healthy. mission XX and the tuned. for coming so commitment a INFINITY the our through today. So for our execute this to you broaden thank pipeline two key safe by opportunities, come our Stay the and as you progress want II all preclinical expect trial, first to year, and advancing team. for trials our am And employees again catalysts continue presenting stay deliver to which to cohorts the concludes focus clinical It's And They so to and and more strong remarkable closing, Adverum Trial. including In at underway, four I time. then, OPTIC DME our evidenced call. a patients And DME therapies II possible. treating year gene make our have demonstrated having humbly for weeks, new I Thank by Phase in our dedication, drive the their Phase been grateful

today's in participating now program and conclude you This the for does you thank may disconnect. gentlemen, and conference. Ladies